Leukemia, Acute
Conditions
Brief summary
Based on the investigator's previous data on risk classification for acute leukemia,the investigators will design a set of panels to detect the gene expression and genomic variants (SNPs, mutation, insertion, deletion and fusion genes, etc), and identify the high-risk subtypes of acute leukemia, such as Ph-like acute lymphoblastic leukemia. Furthermore, the target therapy (Tyrosine Kinase Inhibitors,et.al) will be used to treat the identified patients. In addition, more sensitive minimal residual disease (MRD) detection technology will be designed and used to detect the MRD in patients to early predict the disease relapse.
Detailed description
patient eligibility criteria: newly diagnosed acute leukemia patients with clinical high-risk markers, reflactory and relapsed patients.
Interventions
DIAGNOSTIC_TESTHigh-risk subtype detection panels
The designed detection technology were used to identify the high-risk patients cohort.
Sponsors
Zhongda Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
14 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Newly diagnostic acute lymphoblastic leukemia Be willing to start treatment
Exclusion criteria
* chronic leukemia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| complete remission | From date of randomization or initial treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | Patients achieve complete remission after initial treatment |
| relapse | From date of randomization or complete remission until the date of first documented relapse from any cause, whichever came first, assessed up to 100 weeks | Patients' disease progress after complete remission |
Countries
China
Outcome results
None listed